The audit found a heterogeneous evidence base and a critical route-transfer problem. Cosmetic or laboratory findings must retain their exact intervention and endpoints.
Do not describe systemic injection as established on the strength of topical observations. The same caution applies to efficacy and safety of fixed mixtures.
Sources and proposed-mechanism explanation
Copper-peptide biology and gene-expression observations are offered as a rationale. A large number of affected genes is not a clinical effect-size measure.